Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Adisseo France S A S currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners, meaning each pending matter is handled by a different individual. Furthermore, the actions are split across 2 distinct art units, suggesting that the company's biological and pharmaceutical innovations are being evaluated in different technical departments.
The busiest examiner for this portfolio is STEADMAN, DAVID J, who is responsible for 1 pending office action. With 2 pending office actions in total, the workload is evenly distributed, and no single examiner has a larger influence over the portfolio than the other. This requires the applicant to manage separate examiner relationships and navigate the specific guidelines of 2 distinct art units. The focus on Biotechnology & Pharmaceuticals provides the broad technical umbrella for these filings.
Managing 2 pending office actions across 2 distinct examiners and 2 distinct art units requires a versatile prosecution strategy. Since STEADMAN, DAVID J and the other examiner each manage only one case, there is no opportunity to consolidate responses under a single person. Practitioners must be mindful of the different perspectives within the Biotechnology & Pharmaceuticals sector to ensure that the pending actions are resolved effectively. This structure reflects a diverse but small-scale engagement with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.6% |
| BONAPARTE, AMY C | 1 | 79.3% | +23.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833521 | PROTEIN WITH XYLANASE ACTIVITY | STEADMAN, DAVID J | — |
| 18289196 | Method for producing methionine | BONAPARTE, AMY C | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833521 | PROTEIN WITH XYLANASE ACTIVITY | STEADMAN, DAVID J | 1656 | §112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18289196 | Method for producing methionine | BONAPARTE, AMY C | 1692 | §103 | Final Rejection | — | Pending | Nov 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial